Veradermics' Hair Loss Drug Succeeds in Late-Stage Clinical Trial
Veradermics announced Monday that its oral hair loss medicine VDPHL01 successfully spurred hair growth in a six-month late-stage clinical trial. Men taking the drug once or twice daily grew between 30 and 33 more hairs per square centimeter of scalp, compared to approximately seven additional hairs in the placebo group. Between 79% and 86% of participants reported improvement, while 72% to 84% of investigators observed positive results. The success positions Veradermics, led by dermatologist-turned-CEO Reid Waldman, as one of the most advanced companies in the hair loss field amid surging investor interest in the sector.
Clinical Trial Results and Efficacy Metrics
▪Men who took VDPHL01 once or twice daily grew between 30 and 33 more hairs per square centimeter of scalp over six months.
▪Veradermics assessed VDPHL01 by measuring how many hairs grew within a square centimeter of the scalp on average.
▪Veradermics announced the late-stage clinical trial results for VDPHL01 on Monday.
▪Veradermics' oral hair loss medicine VDPHL01 successfully spurred hair growth in a late-stage clinical trial.
▪Men in the placebo group of the VDPHL01 trial grew approximately seven additional hairs per square centimeter of scalp.
▪The Veradermics clinical trial for VDPHL01 lasted six months.
Patient and Investigator Satisfaction Outcomes
▪Between 79% and 86% of men taking VDPHL01 reported seeing improvement in hair growth.
▪Veradermics assessed VDPHL01 by measuring how satisfied participants were with the results.
▪Reid Waldman is a dermatologist who became Veradermics' chief executive.
▪Between 72% and 84% of clinical trial investigators for VDPHL01 reported seeing improvement in participants.
▪Reid Waldman was pleased with the patient and investigator satisfaction results from the VDPHL01 trial.
Perspective of Veradermics
▪Reid Waldman emphasized the importance of patient and investigator satisfaction as key measures of VDPHL01's success.
▪Veradermics positions itself as one of the most advanced players in the hair loss field following the VDPHL01 trial results.
Perspective of Investors in hair loss treatments
▪Investor interest in the hair loss treatment field has surged amid Veradermics' positive VDPHL01 trial results.
Story comments
Loading comments…